Deciphera Pharmaceuticals, LLC clinical trials

Acquired by Ono Pharmaceutical Co. Ltd, Jun 11, 2024 · source ↗

The registry lists 24 studies whose lead sponsor is Deciphera Pharmaceuticals, LLC. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Ono Pharmaceutical Co. Ltd studies →

• Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male ParticipantsRecruitingNCT07744802Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Study of DCC-2812 in Participants With Advanced Genitourinary CancersRecruitingNCT06966024Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibRecruitingNCT07075471

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)RecruitingNCT06630234Phase 1/2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)RecruitingNCT06619561Phase 2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesActive, not recruitingNCT05957367Phase 1/2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingNCT03673501Phase 3

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)CompletedNCT07539090Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruitingNCT03069469Phase 1/2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsTerminatedNCT04892017Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Study of Vimseltinib for Tenosynovial Giant Cell TumorActive, not recruitingNCT05059262Phase 3

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayTerminatedNCT06287463Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)CompletedNCT07158411Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 SubstrateCompletedNCT07158398Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted after Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibActive, not recruitingNCT05734105Phase 3

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03717415Phase 1/2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03601897Phase 1/2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTCompletedNCT04530981Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer TherapiesCompletedNCT03353753Phase 3

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT05080621Phase 1/2

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GISTApproved for marketingNCT04148092

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• A Study of DCC-2701 in Participants With Advanced Solid TumorsTerminatedNCT02228811Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd

• Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)CompletedNCT00827138Phase 1

  Sponsor listed in the registry: Deciphera Pharmaceuticals, LLC · First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd